Clinical Trial Update: Metformin as a Metabolic Intervention in Oesophageal Adenocarcinomas to Improve Response to Neoadjuvant Chemoradiotherapy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating metformin as a metabolic intervention to improve response to neoadjuvant chemoradiotherapy in esophageal adenocarcinoma, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma

Drugs mentioned

• metformin (metformin)

Snippet

Sponsor: Amsterdam UMC, location VUmc | Conditions: Oesophageal Adenocarcinoma, Tumor Microenvironment | Phase 2 | Status: RECRUITING